TrialBritish journal of haematology2012

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.

Ravi Vij et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.